Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion type Assertion NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_head.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion description "[Co-treatment with VPA and bortezomib on acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) cell lines resulted in marked inhibition of proliferation and induction of apoptosis, including a striking increase in mitochondrial injury, caspase cascade activation, and altered expression of Bcl-2 family proteins.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_provenance.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion evidence source_evidence_literature NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_provenance.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion SIO_000772 21340723 NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_provenance.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion wasDerivedFrom befree-2016 NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_provenance.
- NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_assertion wasGeneratedBy ECO_0000203 NP874201.RA4jXT2Ni908iWdPqL7PpXEdaY0pl6V4AZSp-Hk_4XrHA130_provenance.